CA2867719C - Purification of cystathionine beta-synthase - Google Patents

Purification of cystathionine beta-synthase Download PDF

Info

Publication number
CA2867719C
CA2867719C CA2867719A CA2867719A CA2867719C CA 2867719 C CA2867719 C CA 2867719C CA 2867719 A CA2867719 A CA 2867719A CA 2867719 A CA2867719 A CA 2867719A CA 2867719 C CA2867719 C CA 2867719C
Authority
CA
Canada
Prior art keywords
cbs
protein
column
truncated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2867719A
Other languages
English (en)
French (fr)
Other versions
CA2867719A1 (en
Inventor
Richard G. Carrillo
Jan P. Kraus
Tomas Majtan
David Naveh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of CA2867719A1 publication Critical patent/CA2867719A1/en
Application granted granted Critical
Publication of CA2867719C publication Critical patent/CA2867719C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2867719A 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase Active CA2867719C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US61/615,629 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
US13/830,494 2013-03-14
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Publications (2)

Publication Number Publication Date
CA2867719A1 CA2867719A1 (en) 2013-10-03
CA2867719C true CA2867719C (en) 2020-08-11

Family

ID=49212017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867719A Active CA2867719C (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Country Status (11)

Country Link
US (4) US9243239B2 (cg-RX-API-DMAC10.html)
EP (3) EP3569706A1 (cg-RX-API-DMAC10.html)
JP (3) JP6146934B2 (cg-RX-API-DMAC10.html)
CN (1) CN104540940B (cg-RX-API-DMAC10.html)
AU (1) AU2013240003B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014023570B1 (cg-RX-API-DMAC10.html)
CA (1) CA2867719C (cg-RX-API-DMAC10.html)
HK (1) HK1246350B (cg-RX-API-DMAC10.html)
IL (2) IL234635B (cg-RX-API-DMAC10.html)
IN (1) IN2014DN07920A (cg-RX-API-DMAC10.html)
WO (1) WO2013148580A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) * 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
DK3998067T3 (da) * 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
US20220315965A1 (en) * 2019-06-25 2022-10-06 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
MX2021015966A (es) * 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
CA2788689C (en) 2010-02-04 2019-07-02 The Board Of Regents Of The University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Also Published As

Publication number Publication date
US10160962B2 (en) 2018-12-25
US20190055537A1 (en) 2019-02-21
EP3263701A1 (en) 2018-01-03
AU2013240003A1 (en) 2014-10-02
US9243239B2 (en) 2016-01-26
JP6146934B2 (ja) 2017-06-21
EP3569706A1 (en) 2019-11-20
IL234635B (en) 2018-12-31
US10941392B2 (en) 2021-03-09
EP3263701B1 (en) 2019-06-19
AU2013240003B2 (en) 2018-04-19
JP6952361B2 (ja) 2021-10-20
CA2867719A1 (en) 2013-10-03
JP2015512639A (ja) 2015-04-30
WO2013148580A1 (en) 2013-10-03
BR112014023570B1 (pt) 2022-03-15
HK1246350B (en) 2020-05-15
CN104540940A (zh) 2015-04-22
US20160177287A1 (en) 2016-06-23
EP2831229A1 (en) 2015-02-04
EP2831229B8 (en) 2018-10-17
IL263162B (en) 2019-11-28
US20200131497A1 (en) 2020-04-30
IN2014DN07920A (cg-RX-API-DMAC10.html) 2015-05-01
BR112014023570A2 (pt) 2021-06-01
EP2831229B1 (en) 2017-10-18
CN104540940B (zh) 2018-03-06
JP2017121255A (ja) 2017-07-13
IL263162A (en) 2018-12-31
US20130251700A1 (en) 2013-09-26
JP6839595B2 (ja) 2021-03-10
JP2020000259A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
US10941392B2 (en) Purification of cystathionine beta-synthase
HK1246350A1 (en) Purification of cystathionine beta-synthase
Mihara et al. cDNA cloning, purification, and characterization of mouse liver selenocysteine lyase: candidate for selenium delivery protein in selenoprotein synthesis
US10624959B2 (en) Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
Wu et al. Crystal structure of human spermine synthase: implications of substrate binding and catalytic mechanism*♦
Takata et al. Catalytic mechanism of glycine N-methyltransferase
Wynn et al. Tetrameric assembly and conservation in the ATP-binding domain of rat branched-chain α-ketoacid dehydrogenase kinase
US20040033219A1 (en) Human cystathionine beta-synthase variants and methods of production thereof
Liu et al. Selenocysteine-mediated expressed protein ligation of SELENOM
HK40016298A (en) Purification of cystathionine beta-synthase
AU2011294798B2 (en) Recombinant therapeutic glycine N-acyltransferase
Anguera et al. Cloning, expression, and purification of 5, 10-methenyltetrahydrofolate synthetase from Mus musculus
US20250340852A1 (en) Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine
CN121554529A (zh) 一种具有抗疲劳活性的河鲀多肽及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180117

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321